相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2021)
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Juan Pablo Frias et al.
DIABETES OBESITY & METABOLISM (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
Beatrice Anfuso et al.
SCIENTIFIC REPORTS (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression
Stefanie Wittrisch et al.
MOLECULAR METABOLISM (2020)
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Quentin M. Anstee et al.
JOURNAL OF HEPATOLOGY (2020)
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
Ping An et al.
LIVER INTERNATIONAL (2020)
Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
Henrik H. Hansen et al.
BMC GASTROENTEROLOGY (2020)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2020)
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
Stephen A. Harrison et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Lindsay T. Fourman et al.
JCI INSIGHT (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Manal Abdelmalek et al.
JOURNAL OF HEPATOLOGY (2020)
Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
Richard Aspinall et al.
JOURNAL OF HEPATOLOGY (2020)
VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial
Brian Lian et al.
JOURNAL OF HEPATOLOGY (2020)
EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2020)
Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study
Rajaa Nahra et al.
JOURNAL OF HEPATOLOGY (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes
Mihoko Yoshino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study
Lena M. S. Carlsson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
Olof Eriksson et al.
SCIENTIFIC REPORTS (2020)
AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
Allegra Kaufman et al.
CELL REPORTS MEDICINE (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
Samuel J. Daniels et al.
HEPATOLOGY (2019)
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study
Eiichi Araki et al.
DIABETES OBESITY & METABOLISM (2019)
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo et al.
HEPATOLOGY (2019)
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis[S]
Mei Zhou et al.
JOURNAL OF LIPID RESEARCH (2019)
SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR
Arun Sanyal et al.
JOURNAL OF HEPATOLOGY (2019)
Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Rie Ouchi et al.
CELL METABOLISM (2019)
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M. Anstee et al.
HEPATOLOGY (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease A Systematic Review and Meta-analysis
Dimitrios A. Koutoukidis et al.
JAMA INTERNAL MEDICINE (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials
Elizabeth M. Brunt et al.
HEPATOLOGY (2019)
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
Edgar D. Charles et al.
OBESITY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
E47 modulates hepatic glucocorticoid action
M. Charlotte Hemmer et al.
NATURE COMMUNICATIONS (2019)
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Takara L. Stanley et al.
LANCET HIV (2019)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
Teayoun Kim et al.
DIABETES (2018)
Effects of Pemafibrate, a Novel Selective PPAR alpha Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Eiichi Araki et al.
DIABETES CARE (2018)
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
Benaissa Boubia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
The gut-liver axis and the intersection with the microbiome
Anupriya Tripathi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease
Pik Eu Chang et al.
PLOS ONE (2018)
TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue
Laura A. Velazquez-Villegas et al.
NATURE COMMUNICATIONS (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases
Abdellah Mansouri et al.
GASTROENTEROLOGY (2018)
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
Shanaka Stanislaus et al.
ENDOCRINOLOGY (2017)
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
Cristina Alonso et al.
GASTROENTEROLOGY (2017)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
A Novel Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonist Improves Steatohepatitis and Liver Regeneration in Mice
M. Pilar Valdecantos et al.
HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Bariatric Surgery versus Intensive Medical Therapy for Diabetes-5-Year Outcomes
Philip R. Schauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Mei Zhou et al.
NATURE COMMUNICATIONS (2017)
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
Lindsay T. Fourman et al.
AIDS (2017)
Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
Carmelo Quarta et al.
CELL METABOLISM (2017)
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael A. Nauck et al.
DIABETES CARE (2016)
Sobetirome: the past, present and questions about the future
Jan Lammel Lindemann et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
Shun Ishibashi et al.
ATHEROSCLEROSIS (2016)
Nuclear receptors and nonalcoholic fatty liver diseases
Matthew C. Cave et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease
Brian Finan et al.
CELL (2016)
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar et al.
CELL METABOLISM (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events A Systematic Review and Meta-analysis
Rohan Khera et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study
Cathrine Laustrup Moller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Giovanni Targher et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
Niraj S. Patel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Changtao Jiang et al.
NATURE COMMUNICATIONS (2015)
Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction
Safina Ali et al.
MOLECULAR METABOLISM (2015)
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
Mukul R. Jain et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou et al.
CANCER RESEARCH (2014)
Nuclear Receptors, RXR, and the Big Bang
Ronald M. Evans et al.
CELL (2014)
The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
TinaMarie Lieu et al.
GASTROENTEROLOGY (2014)
Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study
Rohit Loomba et al.
HEPATOLOGY (2014)
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
Martha J. Kelly et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
THYROID HORMONE REGULATION OF METABOLISM
Rashmi Mullur et al.
PHYSIOLOGICAL REVIEWS (2014)
Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways
Daniel F. Vatner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
Rebecca Taub et al.
ATHEROSCLEROSIS (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
FXR signaling in the enterohepatic system
Tsutomu Matsubara et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
The global NAFLD epidemic
Rohit Loomba et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy
Ilkay S. Idilman et al.
RADIOLOGY (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Andrew C. Adams et al.
MOLECULAR METABOLISM (2013)
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
Jamie E. Mells et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
James L. Trevaskis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Successful Weight Loss Among Obese U.S. Adults
Jacinda M. Nicklas et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2012)
Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
Michel Dietz et al.
CHEMMEDCHEM (2012)
Targeted estrogen delivery reverses the metabolic syndrome
Brian Finan et al.
NATURE MEDICINE (2012)
Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex
Ian N. Foltz et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Pre- Versus Postmenopausal Age, Estradiol, and Peptide-Secretagogue Type Determine Pulsatile Growth Hormone Secretion in Healthy Women: Studies Using Submaximal Agonist Drive and an Estrogen Clamp
Susan B. Hudson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Thyroid and Obesity: An Intriguing Relationship
Bernadette Biondi
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation
Ni-Huiping Son et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas et al.
CELL METABOLISM (2009)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity
Roberto Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Julian Falutz et al.
AIDS (2008)
Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality
Nicolas Ochs et al.
ANNALS OF INTERNAL MEDICINE (2008)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans
Anders Berkenstam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index
Mark D. Erion et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists
Yukiyoshi Yamazaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function
Alessandro S. Nascimento et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Farnesoid X receptor is essential for normal glucose homeostasis
K Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
YQ Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A fully dissociated compound of plant origin for inflammatory gene repression
K De Bosscher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver
MD Erion et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy
JT Chang et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2004)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
分享论文
